DiscoveRx Corporation, through its wholly owned Bioseek subsidiary, today announced new findings regarding the safety and toxicity of a variety of chemicals, pharmaceuticals and other materials, tested via the Predictive Tox panel in the company's BioMAP® Systems platform. The new data, described in a series of posters by Bioseek scientists and scientists from U.S. Environmental Protection Agency's ToxCast® program, The Hamner Institute, and Pfizer, were presented this week at the 53rdAnnual Meeting of the Society of Toxicology, held in Phoenix, AZ.
"The data gained through BioMAP screening of a diverse range of substances demonstrate the platform's utility for determining the potential safety of drugs, chemicals and other substances used in the formulation of consumer goods, agricultural chemicals and many other products. Moreover, these findings showcase the BioMAP® platform's value as a tool for characterizing drug and chemical libraries used in high throughput screening, determining compound mechanism of action and prioritizing new drugs and chemicals for development," said Ellen Berg, Ph.D., Scientific Director of Bioseek®. Dr. Berg and her team presented research describing the creation of predictive models based on phenotypic BioMAP Systems data which are capable of classifying drugs and chemicals via their mechanisms of action. A copy of the poster is available for download.
Two further posters provided an overview of the bioactivities and potential toxicity of diverse materials including pharmaceuticals, pesticides, personal care products, industrial chemicals, fragrances, food additives, colorants fruit and vegetable extracts, assessed using BioMAP screening in conjunction with the EPA's ToxCast® program. A fourth poster presented data showing the use of the BioMAP Systems to elucidate the mechanisms by which compounds may elicit drug-induced liver injury (DILI), a clinical adverse outcome responsible for many drug failures. Results suggested that some failed drugs exhibit overt cytotoxicity in multiple cell types, whereas others preferentially showed activity on one system. Moreover, a subset of compounds inhibited the proliferation of multiple cell types, whereas non-DILI compounds were weakly active or inactive.
"Drug-induced liver injury remains a challenge to drug developers and regulatory authorities due to its idiosyncratic nature," said Dr. Ellen Berg. "BioMAP screening provides a window on the mechanisms by which drugs cause such injury in humans, helping us to better understand why drugs fail. Such screening offers the potential to better predict drug toxicities in humans, before entering the clinic."
About DiscoveRx
Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with additional offices in San Diego, CA, San Francisco, CA and Birmingham, England. DiscoveRx is a leading provider of next generation proprietary platforms for both target-based and phenotypic based drug discovery.
The company holds extensive intellectual property for its core technology platforms 1) PathHunter®, HitHunter® and InCELL Hunter™ : ß-galactosidase based enzyme fragment complementation, 2) KINOMEscan® : in vitro binding assay platform and 3) BioMAP® : The BioMAP Systems platform, based on primary human cells and co-cultures, provides a uniquely predictive in vitro tool for investigative toxicology and assessing the mode of action of drugs, chemicals and new materials in the context of human biology. For more information on BioMAP, visit http://www.biomapsystems.com
Utilizing these proprietary platforms, DiscoveRx has developed and commercialized industry leading panels of over 1000 target based and primary cell based assay solutions for Oncology, Metabolic Disease, Inflammation, CNS and Cardiovascular drug discovery research. Many of DiscoveRx's innovative solutions have been widely adopted in pharmaceutical, biotechnology and academic laboratories worldwide. As of November 2012, BioSeek became a wholly owned division of DiscoveRx Corporation. For more information, visit http://www.discoverx.com
CONTACT:
DiscoveRx Corporation
Sailaja Kuchibhatla
Sr. VP Business Development
tel | 510.979.1415 x104
skuchibhatla@discoverx.com
SOURCE: DiscoveRx Corporation
Associated Documentation:
Link to submission on http://www.eteligis.com
DiscoveRx_03-27-2014_MAQ_ETL.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment